This series on “Contemporary Practice in Thoracic Neoplasm Diagnosis, Evaluation and Treatment” is edited by Dr. Chi Wan Koo, from Department of Radiology, Mayo Clinic, Rochester, U.S.A.
Despite increasing public awareness of smoking related morbidity and mortality and implementation of lung cancer screening programs, lung cancer remains the number one cause of cancer related death. As our knowledge of lung cancer pathogenesis advances, approaches to diagnose, surveil and treat lung cancer also evolve. In this series, we seek to update our readers on contemporary practices in thoracic neoplasm diagnosis, evaluation and treatment.
Current practice in thoracic neoplasm diagnosis, evaluation and treatment
Putting artificial intelligence (AI) on the spot: machine learning evaluation of pulmonary nodules
Implications of the updated Lung CT Screening Reporting and Data System (Lung-RADS version 1.1) for lung cancer screening
Thoracic positron emission tomography: 18F-fluorodeoxyglucose and beyond
Changing paradigm in advanced and metastatic non-small cell lung cancer
Proton beam radiotherapy for esophagus cancer: state of the art
Radiation and immunotherapy: emerging mechanisms of synergy
Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors
Immunotherapy in patients with autoimmune disease
Image guided thermal ablation in lung cancer treatment
Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer
Disclosure:
The focused issue “Contemporary Practice in Thoracic Neoplasm Diagnosis, Evaluation and Treatment” was commissioned by the editorial office, Journal of Thoracic Disease without any funding or sponsorship. Chi Wan Koo is serving as the unpaid Guest Editor for the focused issue.